TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00691288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega Pure followed by placebo
Description: Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo followed by Omega Pure
Description: Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
Study: NCT03382418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp145 C.6980 Vaccine
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Adjuvant
Description: Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study: NCT04225013

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
Study: NCT03310632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Study: NCT01821274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem Hydrochloride 2% Cream
Description: 0.2 g applied topically to the infrascapular area of the back.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% solution o sodium lauryl sulfate (SLS)
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Study: NCT04553770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Deruxtecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT01038154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
Study: NCT03338504

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary angiography
Description: Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.

Intervention type: RADIATION
Intervention: CT coronary angiography
Description: CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
Study: NCT00000411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laminectomy
Description: Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
Study: NCT02897466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Antimicrobial Susceptibility Testing
Description: An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
Study: NCT02432209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity
Description: All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate physical activity
Description: All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
Study: NCT02106741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation acupressure
Description: The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulating acupressure
Description: The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes.
Study: NCT01486823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLDL1278A
Description: Single subcutaneous dose of 360 mg MLDL1278A.
Study: NCT00893529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lemonade with sugar
Description: 250 milliliters of lemonade with sugar daily for 18 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lemonade low in sugar
Description: 250 milliliters of lemonade low in sugar daily for 18 months
Study: NCT03092648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cell
Description: autologous bronchial basal cell transplantation
Study: NCT02273128

Intervention type: GENETIC
Intervention: CTR Gene
Description: 2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
Study: NCT04388176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 as first treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 as second treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as second treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as first treatment
Study: NCT02934555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: 300 mg Ubiquinol (3 mL liquid Ubiquinol).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ensure
Description: 50 mL Ensure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: 50 mL Ensure
Study: NCT01199887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW001
Description: IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
Study: NCT05857410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetomidine
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb heating blanket
Description: Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb heating blanket
Description: Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
Study: NCT04291118

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Private system endoscopic sinus surgery
Description: Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Public system endoscopic sinus surgery
Description: Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide
Description: Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
Study: NCT01423929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Fitting of Oxymask TM and treatment with 10 L O2/min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Room air
Description: Fitting of Oxymask TM
Study: NCT02555917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cruciate ligament reconstruction
Description: Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
Study: NCT00200577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIL + IL2
Description: Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
Study: NCT04337021

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver SOS
Description: SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
Study: NCT00758381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg po bid, continuously
Description: NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabina, Cisplatino
Description: Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
Study: NCT00048633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study: NCT04900649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest resistance exercise
Description: lung function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest expansion exercises
Description: thoracic excursion
Study: NCT01403571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salba (Salvia hispanica L.)
Description: 30g/1000kcal/day over 24 wks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat-based Control
Description: Placebo: 36g/1000kcal/day over 24 weeks
Study: NCT02344511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin, nafcillin, oxacillin or vancomycin
Description: Standard of Care
Study: NCT04636411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Magnesium Supplementation
Description: 250 mg of elemental magnesium daily for three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care for diabetic patients
Description: Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care for diabetic patients
Description: Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
Study: NCT01319942

Intervention type: OTHER
Intervention: Radiotherapy combined with sorafenib
Description: Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
Study: NCT01388712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
Study: NCT03914274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technical sock
Description: Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
Study: NCT02729480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo Craniofacial Nerve Stimulator System
Description: The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Halo Craniofacial Nerve Stimulator System
Description: The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
Study: NCT02149264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel (FE 999303)
Study: NCT04329845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open splenectomy
Description: open splenectomy for treatment of splenic injury

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic splenectomy for splenic injury in trauma
Description: laparoscopy as a technique for removal of the spleen in injury
Study: NCT01610869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBF 1120
Description: Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
Study: NCT01184170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overfeeding
Description: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.